Video Series

The esteemed panel concludes with their final thoughts on CKD therapies and management.

Drs Feldman, Pitt, and Agarwal describe the common CKD health disparities seen at their institutions and the steps they have taken to address them.

Paul Noble, MD, provides his closing thoughts on payer perspectives surrounding ILD, as well as considerations for the trajectory of ILD treatment landscape.

Nintedanib recommendations for use from the recent ATS guidelines and treatment implementation are considered by Paul Noble, MD.

Amer Zeidan, MBBS, MHS, navigates prognostic models utilized for considerations surrounding patients with lower-risk and higher-risk MDS.

Ryan Haumschild, PharmD, MS, MBA, leads expert panelists in a conversation exploring the prevalence and clinical burden impact of MDS.

Sonia Oskouei explores the managed care landscape and opportunities for increasing biosimilar uptake to improve patient care.

Evolving treatment strategies for esophagogastric cancer are explored by Syma Iqbal, MD, including unmet needs across the treatment landscape.

Syma Iqbal, MD, provides insights pertaining to various types of upper GI cancers, as well as primary characteristics and risk factors for these diseases.

Dr King presents interleukin-15, a non-JAK inhibitor therapy option for the treatment of vitiligo.

Safety considerations, particularly surrounding JAK inhibitors in vitiligo treatment, are emphasized by the panelists.

Millie Das, MD, shares key takeaways from her presentation regarding cost-effective strategies and payer considerations related to the treatment of NSCLC.

Dr Bertram Pitt explains the possibility of combining SGLT2 inhibitors and MRAs when treating CKD and CV, and Paul Sapia, MHA, discusses how payers balance cost of care with disease progression and health disparities.

Dr Jeffrey Feldman discusses finerenone trial data and the role that it and SGLT2 inhibitors have played in patients with CKD.

Dr Noble discusses recent ATS guidelines regarding the use of pirfenidone in ILD.

ILD treatment options approved by the FDA are explored by Dr Noble, MD.

Key opinion leaders discuss the impact MDS can have on the quality of life for patients compared with other hematologic disease states.

A panel of experts open a discussion on the expanding awareness of myelodysplastic syndromes (MDS).

Dr Rosmarin illustrates treatment management of vitiligo with the use of JAK inhibitors.

The panel navigates unmet needs surrounding the vitiligo treatment landscape.

The panel of experts provide their final insights regarding unmet needs surrounding treatment management of heart failure.

Experts share their thoughts on payer and provider perceptions surrounding affordable HF care, as well as strategies to manage care-associated costs.

Multiple comorbidities lead to an emphasis on multidisciplinary care management when determining the most effective HF treatment strategies.

IMpower010 trial data may influence a significant evolution in treatment of non–small cell lung cancer.

Sonia T. Oskouei, PharmD, BCMAS, DPLA, navigates the impact of the VOLTAIRE-X study, the only published switching study for adalimumab, on biosimilar uptake.

Dr Noble, MD provides and overview of the treatment landscape surrounding ILD, specifically examining IPF, PPF, and SSc-ILD antifibrotic therapy.

Dr Paul Noble, MD discusses updates and changes in ATS-directed guidelines for the treatment of ILD.

Dr Agarwal provides a deep dive into the use of nonsteroidal mineralocorticoid receptor antagonists in CKD therapy.

Dr Feldman concludes the treatment landscape overview by discussing glycemic control, SGLT2 inhibitors, and other important management techniques.

Dr Millie Das, MD opens a discussion surrounding updates regarding non-small cell lung cancer (NSCLC) as presented at the 2022 World Conference on Lung Cancer (WCLC).